iBio is a clinical stage biotech developing AI designed antibody drugs for obesity and related heart and lung diseases. IBIO reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 17 | HC Wainwright & Co. | Initiated | Buy | |
| Jun 8 | Raymond James | Initiated | Buy |
Seasonality
How IBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2008.
Whale Options Flow
90DNo whale options trades in IBIO in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IBIO is in one of them and how their past IBIO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IBIO in an article yet. Here's the latest on the wider market.
About iBio
iBio is a biotechnology company that uses artificial intelligence to design antibody drugs. Its work focuses on obesity and related heart and lung conditions, including pulmonary hypertension linked to heart failure. Its lead candidate, IBIO-600, is in a Phase 1 clinical trial, and other candidates are in earlier preclinical development. No products are approved yet, so its intended customers are patients with these conditions and the clinicians who treat them. The company is based in New York and conducts its research at a laboratory in San Diego.
- Headquarters
- New York, NY